Outlook Therapeutics, Inc. Forecast, price target & analysts
Outlook Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Outlook Therapeutics, Inc. Classifications & Recommendation
Outlook Therapeutics, Inc. Price Target
| Target Price | $4.08 |
| Price | $0.64 |
| Potential |
538.00%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Outlook Therapeutics, Inc. 2027 .
The average Outlook Therapeutics, Inc. target price is $4.08.
This is
538.00%
register free of charge
$10.50
1,541.91%
register free of charge
$1.62
152.70%
register free of charge
|
|
| A rating was issued by 10 analysts: 7 Analysts recommend Outlook Therapeutics, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Outlook Therapeutics, Inc. stock has an average upside potential 2027 of
538.00%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.41 | 26.66 |
| 1,790.50% | ||
| Net Margin | -4,426.95% | -353.20% |
| 92.02% |
6 Analysts have issued a sales forecast Outlook Therapeutics, Inc. 2026 . The average Outlook Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Outlook Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Outlook Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.79 | -0.50 |
| 55.91% | 72.07% | |
| P/E | negative | |
| EV/Sales | 6.10 |
6 Analysts have issued a Outlook Therapeutics, Inc. forecast for earnings per share. The average Outlook Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Outlook Therapeutics, Inc....
Current Outlook Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Jun 11 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | May 18 2026 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Mar 11 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jul 27 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 27 2026 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Jun 11 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
May 18 2026 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Mar 11 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
